Medtronic | MDT Stock Price, Company Overview & News (original) (raw)

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, an... Read More

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland. Read Less

Industry

Health Care Equipment & Services

Founded

1949

Headquarters

Dublin

Country/Territory

Ireland

Chief Executive Officer

Geoffrey Straub Martha

Employees

95,000

Forbes Lists

#191

#386 - SALES

#241 - PROFITS

#435 - ASSETS

#129 - MARKET VALUE

Medtronic Financial Summary

Sources

FactSet, Bloomberg, S&P Cap IQ; Forbes.

SummaryAdditional DataAnalystsHistorical Quotes

Key Data

52 Week Range

75.96 x 92.68

Ex-Dividend Date

Dec 27, 2024

Valuation Measures

Price to Book Value (ttm)

2.25

Price to Tangible Book Value (ttm)

N/A

Total Enterprise Value to EBIT (ttm)

19.91

Total Enterprise Value to EBITDA (ttm)

13.77

Total Enterprise Value to Total Revenue (ttm)

3.94

Profitability Metrics

Operating Margin (ttm)

19.77%

Return on Assets (ttm)

4.53%

Return on Equity (ttm)

8.61%

Revenue and Earnings Metrics

Revenue Per Share (ttm)

25.25

Revenue Growth (y/o/y)

3.25%

EBITDA Growth (y/o/y)

4.26%

Diluted EPS Growth (y/o/y)

6.04

Cash and Debt Metrics

All values as of most recently reported quarter unless otherwise noted.

Consensus Recommendation

Outperform

Range of Price Targets

82.00 to 112.00

Range of Revenue 34Bto34B to 34Bto34.51B

DATE OPEN HIGH LOW CLOSE ADJUSTED CLOSE VOLUME
Jan 14, 2025 83.39 85.31 83.11 85.25 85.25 12,690,639,000,000,000
Jan 13, 2025 80.91 82.12 80.01 81.79 81.79 6,487,705
Jan 10, 2025 82.00 82.49 80.51 80.66 80.66 7,068,239
Jan 8, 2025 80.41 83.22 80.35 82.68 82.68 11,154,164
Jan 7, 2025 80.37 81.07 79.74 79.87 79.87 7,363,342
Jan 6, 2025 80.52 81.14 79.66 79.84 79.84 7,886,375
Jan 3, 2025 80.50 81.00 79.98 80.95 80.95 5,394,979
Jan 2, 2025 80.37 80.67 79.86 80.22 80.22 5,575,206
Dec 31, 2024 79.82 80.23 79.38 79.88 79.88 4,803,813

Related People & Companies